CoChat

Overall and cause-specific mortality in GH-deficient adults on GH replacement

Gaillard, Rolf C, Mattsson, Anders F, Åkerblad, Ann-Charlotte, Bengtsson, Bengt-Åke, Cara, José, Feldt-Rasmussen, Ulla, Kołtowska-Häggström, Maria, Monson, John P, Saller, Bernhard, Wilton, Patrick, Abs, Roger · 2012 · European Journal of Endocrinology
Cited by 130

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Objective: Hypopituitarism is associated with an increased mortality rate but the reasons underlying this have not been fully elucidated. The purpose of this study was to evaluate mortality and associated factors within a large GH-replaced population of hypopituitary patients. Design: In KIMS (Pfizer International Metabolic Database) 13 983 GH-deficient patients with 69 056 patient-years of follow-up were available. Methods: This study analysed standardised mortality ratios (SMRs) by Poisson regression. IGF1 SDS was used as an indicator of adequacy of GH replacement. Statistical significance was set to P<0.05. Results: All-cause mortality was 13% higher compared with normal population rates (SMR, 1.13; 95% confidence interval, 1.04–1.24). Significant associations were female gender, younger age at follow-up, underlying diagnosis of Cushing's disease, craniopharyngioma and aggressive tumour and presence of diabetes insipidus. After controlling for confounding factors, there were statistically significant negative associations between IGF1 SDS after 1, 2 and 3 years of GH replacement and SMR. For cause-specific mortality there was a negative association between 1-year IGF1 SDS and SMR for deaths from cardiovascular diseases (P=0.017) and malignancies (P=0.044). Conclusions: GH-replaced patients with hypopituitarism demonstrated a modest increase in mortality rate; this appears lower than that previously published in GH-deficient patients. Factors associated with increased mortality included female gender, younger attained age, aetiology and lower IGF1 SDS during therapy. These data indicate that GH replacement in hypopituitary adults with GH deficiency may be considered a safe treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1530/eje-11-1028

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 130

Metadata

Authors
Gaillard, R. C., Mattsson, A. F., Åkerblad, A.-C., Bengtsson, B.-Å., Cara, J., Feldt-Rasmussen, U., Kołtowska-Häggström, M., Monson, J. P., Saller, B., Wilton, P., & Abs, R.
Venue
European Journal of Endocrinology
Published
2012-06
Volume
166
Issue
6
Pages
1069-1077
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
OpenAlex
W2111671114
Cited by
130
References
9
FWCI
12.20
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Overall and cause-specific mortality in GH-deficient adults on GH replacement. https://app.cochat.ai/papers/10.1530/eje-11-1028
The paper
Gaillard, R. C., Mattsson, A. F., Åkerblad, A.-C., Bengtsson, B.-Å., Cara, J., Feldt-Rasmussen, U., Kołtowska-Häggström, M., Monson, J. P., Saller, B., Wilton, P., & Abs, R. (2012). Overall and cause-specific mortality in GH-deficient adults on GH replacement. European Journal of Endocrinology. https://doi.org/10.1530/eje-11-1028

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.